MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER
Leapman M, Nguyen H, Cowan J, Porten S, Meng M, Cooperberg M, Carroll P. MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER. Journal Of Urology 2016, 195: e1043. DOI: 10.1016/j.juro.2016.02.2033.Peer-Reviewed Original ResearchPhosphodiesterase type 5 inhibitor useType 5 inhibitor useInhibitor useBiochemical recurrenceProstate cancer